Sobi Partnership to Advance Gamifant as Interferon-gamma-driven Sepsis Treatment

11:17 PM EST, 01/07/2026 (MT Newswires) -- Swedish Orphan Biovitrum (SOBI.ST), or Sobi, and its partner, the Hellenic Institute for the Study of Sepsis, decided to advance Gamifant, or emapalumab, as a treatment for interferon-gamma-driven sepsis following the phase 2a Embrace trial. The Swedish biopharmaceutical company reported that the study showed proof-of-concept and indications of improvement in organ dysfunction and survival, according to a Wednesday release. The data will be presented during an upcoming medical conference. Sobi will discuss the next steps in the development of the medication with regulators.